Objective Steatotic liver disease (SLD) is a prevalent chronic liver disease for which lifestyle intervention remains the first-line treatment. However, reliable biomarkers that reflect treatment responsiveness are limited. MicroRNA-122 (miR-122) is a liver-specific microRNA involved in hepatic lipid metabolism and injury. However, its clinical significance during lifestyle intervention has not yet been fully elucidated.
Eriksson et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: